Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + Capecitabine Phase Ib in Advanced Solid Tumors
NCT02494596Phase 1Completed
- Sponsor
- Roche
- Start
- Jan 2004
- Primary completion
- Sep 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of pertuzumab in solid tumor (3 arms), sponsored by Roche. Primary endpoint: Maximum Tolerated Dose. Started Jan 2004; status: completed.
02
Drugs
pertuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02494596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02494596.